Are weight-loss medicines like semaglutide relevant for people with heart failure in the UK? 

For many years, the primary treatments for heart failure focused on the ‘Four Pillars’ of medication to support the heart’s pumping action. However, for the millions of people in the UK living with heart failure with preserved ejection fraction (HFpEF), where the heart is stiff rather than weak, options were but limited. In 2024 and 2025, a major shift occurred. We now recognize that obesity is often a root cause, not just a complication, of this condition. Weight-loss medicines like semaglutide (Wegovy) have emerged as powerful tools that can transform the health of heart failure patients by directly addressing this underlying driver. 

What We’ll Discuss in This Article 

• The clinical link between obesity and heart failure 

• Key findings from the STEP-HFpEF and SELECT trials 

• Why semaglutide is considered a breakthrough for HFpEF 

• Current NHS eligibility and NICE appraisal status 

• Potential benefits beyond weight loss (inflammation and diuretics) 

• Side effects and monitoring requirements 

• The spiritual perspective on medical innovation 

The Clinical Breakthrough: STEP-HFpEF 

The relevance of semaglutide for heart failure was solidified by a landmark study called the STEP-HFpEF trial. 

What the research showed: 

• Symptom Relief: Patients taking a weekly 2.4mg dose of semaglutide reported a significant reduction in breathlessness and fatigue. 

• Exercise Capacity: On average, participants were able to walk about 20 metres further in a six-minute walk test compared to those on a placebo. 

• Disease Modification: Many patients were able to reduce their dose of water tablets (diuretics) as their heart function and fluid balance improved. 

• Weight Loss: Participants lost an average of 10% to 15% of their body weight over a year, significantly reducing the physical workload on the heart. 

Is it available on the NHS? 

As of late 2025, the availability of semaglutide specifically for heart failure in the UK is in a transitional phase. 

1. Specialist Weight Management (Tier 3) 

Wegovy is currently available through NHS specialist weight management services for individuals with a BMI of 35 or more (or 32.5 for certain ethnic groups) who also have a weight-related condition like heart failure. 

2. Type 2 Diabetes 

If you have heart failure and Type 2 diabetes, you may already be eligible for semaglutide (Ozempic or Rybelsus) through your GP or diabetes clinic to help manage your blood sugar and cardiovascular risk. 

3. Cardiovascular Risk Reduction 

In July 2024, the MHRA approved Wegovy specifically to reduce the risk of heart attacks and strokes in people with cardiovascular disease and obesity. NICE is currently finalising its guidance on how this will be funded across the NHS, with widespread availability expected to increase through 2026. 

How it Helps the Heart 

Semaglutide does more than just help you eat less. It has several direct effects on the cardiovascular system: 

• Anti-inflammatory: It reduces systemic inflammation, which is a major driver of heart stiffness in HFpEF. 

• Fluid Regulation: By improving kidney function and reducing fat around the heart, it helps the body manage fluid more effectively. 

• Metabolic Support: It improves how the heart muscle uses energy, making it more resilient under stress. 

Side Effects and Safety 

While semaglutide is a advancement, it is not suitable for everyone and requires careful monitoring. 

• Gastrointestinal Issues: The most common side effects are nausea, vomiting, and diarrhoea, particularly during the dose-escalation phase. 

• Pancreatitis Risk: There is a small but risk of inflammation of the pancreas; patients must report severe abdominal pain immediately. 

• Muscle Loss: Rapid weight loss can lead to muscle wasting. It is essential to combine this medicine with a high-protein diet and resistance exercise to protect your heart and skeletal muscles. 

Spiritual Reflection on Medical Progress 

In the Quran, we are encouraged to reflect on the signs of God’s mercy and the knowledge he bestows upon mankind to alleviate suffering. 

‘And We send down of the Quran that which is a healing and a mercy for the believers.’ 

The development of medicines that can target the root causes of disease is a manifestation of this healing. holy Prophet Muhammad taught that for every disease, there is a cure, and we are encouraged to seek it. Using advanced treatments like semaglutide to restore the health of the heart is a way of preserving the gift of life. holy Prophet Muhammad said: ‘Make use of medical treatment, for God has not made a disease without appointing a remedy for it.’ 

Conclusion 

Weight-loss medicines like semaglutide represent one of the most significant leaps in heart failure care in the last decade, particularly for those with obesity-related HFpEF. By reducing body fat, lowering inflammation, and improving the heart’s efficiency, these treatments offer hope for a life with fewer symptoms and greater mobility.¹¹ While NHS access is currently focused on specialist clinics, the evidence supporting its use for heart failure continues to grow. If you feel you fit the criteria, the best next step is to discuss a referral to a specialist weight management service with your cardiologist or GP. 

Emergency Guidance 

If you are taking semaglutide and experience severe, persistent stomach pain that radiates to your back, or if you become severely dehydrated due to vomiting, seek medical attention immediately. These can be signs of serious complications that require urgent expert review. 

Authority Snapshot 

This article was written by Dr. Stefan Petrov, a UK-trained physician with experience in general medicine, emergency care, and intensive care units. Dr. Petrov has closely followed the evolution of cardiorenal medicine in the NHS, particularly the emerging role of GLP-1 receptor agonists in managing heart failure. This guide is based on the latest evidence from the STEP-HFpEF and SELECT trials, alongside current MHRA and NICE standing as of late 2025.